KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Receivables - Accured (2020 - 2024)

Vir Biotechnology (VIR) has disclosed Revenue - Other for 6 consecutive years, with $1.9 million as the latest value for Q1 2023.

  • Quarterly Revenue - Other fell 26.92% to $1.9 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $25.8 million through Mar 2023, up 164.27% year-over-year, with the annual reading at $26.4 million for FY2022, 216.28% up from the prior year.
  • Receivables - Accured hit $5.7 million in Q1 2024 for Vir Biotechnology, up from $4.0 million in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $5.7 million in Q1 2024 to a low of $600000.0 in Q2 2021.
  • Historically, Receivables - Accured has averaged $2.1 million across 5 years, with a median of $1.8 million in 2022.
  • Biggest five-year swings in Revenue - Other: soared 512.5% in 2020 and later crashed 87.76% in 2021.
  • Year by year, Revenue - Other stood at -$2.5 million in 2019, then soared by 404.0% to $7.6 million in 2020, then tumbled by 58.59% to $3.1 million in 2021, then surged by 503.75% to $19.0 million in 2022, then tumbled by 90.0% to $1.9 million in 2023.
  • Business Quant data shows Revenue - Other for VIR at $1.9 million in Q1 2023, $19.0 million in Q4 2022, and $2.8 million in Q3 2022.